Kronos Bio presented promising preclinical data on KB-9558, a p300 KAT inhibitor targeting HPV-driven tumors, with potential for targeted therapy.

Kronos Bio announced promising preclinical data on its p300 KAT inhibitor, KB-9558, targeting HPV-driven tumors, including head, neck, cervical, and anogenital cancers. Presented at the EORTC-NCI-AACR Symposium, the study revealed that inhibiting p300 KAT activity selectively reduces the expression of HPV oncogenes E6 and E7, restoring tumor suppressor pathways p53 and Rb. Currently, no targeted therapies exist for these oncogenes, highlighting KB-9558's potential.

October 23, 2024
3 Articles

Further Reading